Gustavo A. Rosario Benitez

Array ( [id] => 17611562 [patent_doc_number] => 20220153841 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-19 [patent_title] => ANTI-ALPHABETATCR ANTIBODY [patent_app_type] => utility [patent_app_number] => 17/511218 [patent_app_country] => US [patent_app_date] => 2021-10-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13010 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17511218 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17383902 [patent_doc_number] => 20220031754 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-03 [patent_title] => CELLS COMPRISING NON-HLA RESTRICTED T CELL RECEPTORS [patent_app_type] => utility [patent_app_number] => 17/505515 [patent_app_country] => US [patent_app_date] => 2021-10-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28701 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 52 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17505515 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17356797 [patent_doc_number] => 20220017593 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-20 [patent_title] => COMPOSITIONS AND METHODS FOR USE OF RECOMBINANT T CELL RECEPTORS FOR DIRECT RECOGNITION OF TUMOR ANTIGEN [patent_app_type] => utility [patent_app_number] => 17/496580 [patent_app_country] => US [patent_app_date] => 2021-10-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6008 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 69 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17496580 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17356797 [patent_doc_number] => 20220017593 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-20 [patent_title] => COMPOSITIONS AND METHODS FOR USE OF RECOMBINANT T CELL RECEPTORS FOR DIRECT RECOGNITION OF TUMOR ANTIGEN [patent_app_type] => utility [patent_app_number] => 17/496580 [patent_app_country] => US [patent_app_date] => 2021-10-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6008 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 69 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17496580 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17576941 [patent_doc_number] => 20220133796 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-05 [patent_title] => FUSION PROTEIN FOR USE IN THE TREATMENT OF HVG DISEASE [patent_app_type] => utility [patent_app_number] => 17/494610 [patent_app_country] => US [patent_app_date] => 2021-10-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8325 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 79 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17494610 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20129359 [patent_doc_number] => 12371663 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-07-29 [patent_title] => Engineered gd T-cells [patent_app_type] => utility [patent_app_number] => 17/493685 [patent_app_country] => US [patent_app_date] => 2021-10-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 25296 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 175 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17493685 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17356837 [patent_doc_number] => 20220017633 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-20 [patent_title] => HUMANIZED BCMA ANTIBODY AND BCMA-CAR-T CELLS [patent_app_type] => utility [patent_app_number] => 17/493386 [patent_app_country] => US [patent_app_date] => 2021-10-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3950 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17493386 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20129359 [patent_doc_number] => 12371663 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-07-29 [patent_title] => Engineered gd T-cells [patent_app_type] => utility [patent_app_number] => 17/493685 [patent_app_country] => US [patent_app_date] => 2021-10-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 25296 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 175 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17493685 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17578833 [patent_doc_number] => 20220135688 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-05 [patent_title] => FUSION PROTEIN FOR USE IN THE TREATMENT OF HVG DISEASE [patent_app_type] => utility [patent_app_number] => 17/488811 [patent_app_country] => US [patent_app_date] => 2021-09-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8928 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17488811 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17578833 [patent_doc_number] => 20220135688 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-05 [patent_title] => FUSION PROTEIN FOR USE IN THE TREATMENT OF HVG DISEASE [patent_app_type] => utility [patent_app_number] => 17/488811 [patent_app_country] => US [patent_app_date] => 2021-09-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8928 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17488811 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17578833 [patent_doc_number] => 20220135688 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-05 [patent_title] => FUSION PROTEIN FOR USE IN THE TREATMENT OF HVG DISEASE [patent_app_type] => utility [patent_app_number] => 17/488811 [patent_app_country] => US [patent_app_date] => 2021-09-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8928 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17488811 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17336048 [patent_doc_number] => 20220002379 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-06 [patent_title] => SURROGATE CO-RECEPTORS FOR T CELLS AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 17/479898 [patent_app_country] => US [patent_app_date] => 2021-09-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14580 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 64 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17479898 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17314481 [patent_doc_number] => 20210403529 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-30 [patent_title] => TCR-ENRICHED CLONOTYPE, ACQUISITION METHOD AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/475686 [patent_app_country] => US [patent_app_date] => 2021-09-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3413 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17475686 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17482277 [patent_doc_number] => 20220089781 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-24 [patent_title] => Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation [patent_app_type] => utility [patent_app_number] => 17/470386 [patent_app_country] => US [patent_app_date] => 2021-09-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 74377 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17470386 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17428701 [patent_doc_number] => 20220056409 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-24 [patent_title] => T-CELL RECEPTOR-DEFICIENT T CELL COMPOSITIONS [patent_app_type] => utility [patent_app_number] => 17/463605 [patent_app_country] => US [patent_app_date] => 2021-09-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16766 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17463605 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17460574 [patent_doc_number] => 20220073879 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-10 [patent_title] => ENHANCED GENERATION OF CYTOTOXIC T-LYMPHOCYTES BY IL-21 MEDIATED FOXP3 SUPPRESSION [patent_app_type] => utility [patent_app_number] => 17/400038 [patent_app_country] => US [patent_app_date] => 2021-08-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9984 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17400038 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17460574 [patent_doc_number] => 20220073879 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-10 [patent_title] => ENHANCED GENERATION OF CYTOTOXIC T-LYMPHOCYTES BY IL-21 MEDIATED FOXP3 SUPPRESSION [patent_app_type] => utility [patent_app_number] => 17/400038 [patent_app_country] => US [patent_app_date] => 2021-08-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9984 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17400038 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17385608 [patent_doc_number] => 20220033460 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-03 [patent_title] => IDENTIFICATION AND USE OF T CELL EPITOPES IN DESIGNING DIAGNOSTIC AND THERAPEUTIC APPROACHES FOR COVID-19 [patent_app_type] => utility [patent_app_number] => 17/397841 [patent_app_country] => US [patent_app_date] => 2021-08-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 77322 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17397841 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17292240 [patent_doc_number] => 20210388079 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-16 [patent_title] => NOVEL T CELL RECEPTORS AND IMMUNE THERAPY USING THE SAME [patent_app_type] => utility [patent_app_number] => 17/397656 [patent_app_country] => US [patent_app_date] => 2021-08-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22784 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 224 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17397656 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19339323 [patent_doc_number] => 12049501 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-07-30 [patent_title] => CD3-binding molecules capable of binding to human and non-human CD3 [patent_app_type] => utility [patent_app_number] => 17/393682 [patent_app_country] => US [patent_app_date] => 2021-08-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 36 [patent_no_of_words] => 34790 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 137 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17393682 [rel_patent_id] =>[rel_patent_doc_number] =>)